Thank you for your
interest in NK-92®cells

ImmunityBio is the originator, proprietor and custodian of NK-92, the widely known natural killer cell line, established in continuous culture in 1992.

ImmunityBio makes these cells available for patent identity purposes and for basic science research by not-for-profit entities through a limited-use license or material transfer agreement, provided that such limited-use excludes value creation of an exclusive nature that can be subsequently exploited commercially, directly or indirectly.

All such excluded uses, irrespective of the non-profit status of the requesting entity, shall require a commercial license, as described below.

ImmunityBio’s Proprietary
NK-92 Cell Line

ImmunityBio has designated and exclusively authorized its affiliate, Brink Biologics, Inc., to make, license and distribute ImmunityBio’s proprietary NK-92 cells and its derivatives available to ‘for-profit’ entities for non-clinical applications.

For-profit entities require a license, irrespective of intended use. Access to our cells for such non-clinical applications as in vitro testing for product discovery, research and development, and bioanalytical testing as part of commercial manufacturing, are provided through Brink Biologic’s Neukopanel® Licensing Program.

Brink Biologics holds the exclusive rights to and is the only authorized distributor of NK-92, NK-92MI and all NK-92.CD16 variants for non-clinical use by for-profit entities worldwide. To begin the process, please click the button below.

Parties interested in clinical applications of our NK-92 cells and its derivatives may click the button below to inquire further.

Please visit the Brink Biologics website to start a licensing request.

Brink Biologics log

Brink Biologics Licensing Process:

Fill out request form

Receive, review, and sign NDA

Review term sheet for license

Discuss details of license, finalize, sign and pay fees

Obtain cells under license

Please click the logo below to return to the ImmunityBio website.

BrinkBiologics Logo

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.